| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Transplantation Research,
Core Technology, and
Nervous System Research, Novartis Pharma, Basel, Switzerland; and
Novartis Research Institute, Vienna, Austria
We report here on the characterization of the novel immunosuppressant Sanglifehrin A (SFA). SFA is a representative of a class of macrolides produced by actinomycetes that bind to cyclophilin A (CypA), the binding protein of the fungal cyclic peptide cyclosporin A (CsA). SFA interacts with high affinity with the CsA binding side of CypA and inhibits its peptidyl-prolyl isomerase activity. The mode of action of SFA is different from known immunosuppressive drugs. It has no effect on the phosphatase activity of calcineurin, the target of the immunosuppressants CsA and FK506 when complexed to their binding proteins CypA and FK binding protein, respectively. Moreover, its effects are independent of binding of cyclophilin. SFA inhibits alloantigen-stimulated T cell proliferation but acts at a later stage than CsA and FK506. In contrast to these drugs, SFA does not affect IL-2 transcription or secretion. However, it blocks IL-2-dependent proliferation and cytokine production of T cells, in this respect resembling rapamycin. SFA inhibits the proliferation of mitogen-activated B cells, but, unlike rapamycin, it has no effect on CD154/IL-4-induced Ab synthesis. The activity of SFA is also different from that of other known late-acting immunosuppressants, e.g., mycophenolate mofetil or brequinar, as it does not affect de novo purine and pyrimidine biosynthesis. In summary, we have identified a novel immunosuppressant, which represents, in addition to CsA, FK506 and rapamycin, a fourth class of immunophilin-binding metabolites with a new, yet undefined mechanism of action.
This article has been cited by other articles:
|
|
 |
|
  J.-P. Evenou, J. Wagner, G. Zenke, V. Brinkmann, K. Wagner, J. Kovarik, K. A. Welzenbach, G. Weitz-Schmidt, C. Guntermann, H. Towbin, et al. The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 792 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pan, C. Luo, R. Li, A. Qiao, L. Zhang, M. Mines, A. M. Nyanda, J. Zhang, and G.-H. Fan Cyclophilin A Is Required for CXCR4-mediated Nuclear Export of Heterogeneous Nuclear Ribonucleoprotein A2, Activation and Nuclear Translocation of ERK1/2, and Chemotactic Cell Migration J. Biol. Chem., January 4, 2008; 283(1): 623 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zollinger, F. Waldmeier, S. Hartmann, G. Zenke, A. G. Zimmerlin, U. Glaenzel, J.-P. Baldeck, A. Schweitzer, S. Berthier, T. Moenius, et al. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO Drug Metab. Dispos., May 1, 2006; 34(5): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kallen, R. Sedrani, G. Zenke, and J. Wagner Structure of Human Cyclophilin A in Complex with the Novel Immunosuppressant Sanglifehrin A at 1.6 A Resolution J. Biol. Chem., June 10, 2005; 280(23): 21965 - 21971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, F. Erdmann, R. Baumgrass, M. Schutkowski, and G. Fischer Unexpected Side Chain Effects at Residue 8 of Cyclosporin A Derivatives Allow Photoswitching of Immunosuppression J. Biol. Chem., February 11, 2005; 280(6): 4842 - 4850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sokolskaja, D. M. Sayah, and J. Luban Target Cell Cyclophilin A Modulates Human Immunodeficiency Virus Type 1 Infectivity J. Virol., December 1, 2004; 78(23): 12800 - 12808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Woltman, N. Schlagwein, S. W. van der Kooij, and C. van Kooten The Novel Cyclophilin-Binding Drug Sanglifehrin A Specifically Affects Antigen Uptake Receptor Expression and Endocytic Capacity of Human Dendritic Cells J. Immunol., May 15, 2004; 172(10): 6482 - 6489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Allen, Y. Zheng, L. Gardner, M. Safford, M. R. Horton, and J. D. Powell The Novel Cyclophilin Binding Compound, Sanglifehrin A, Disassociates G1 Cell Cycle Arrest from Tolerance Induction J. Immunol., April 15, 2004; 172(8): 4797 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Baumgrass, Y. Zhang, F. Erdmann, A. Thiel, M. Weiwad, A. Radbruch, and G. Fischer Substitution in Position 3 of Cyclosporin A Abolishes the Cyclophilin-mediated Gain-of-function Mechanism but Not Immunosuppression J. Biol. Chem., January 23, 2004; 279(4): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boulay, S. Zumstein-Mecker, C. Stephan, I. Beuvink, F. Zilbermann, R. Haller, S. Tobler, C. Heusser, T. O'Reilly, B. Stolz, et al. Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells Cancer Res., January 1, 2004; 64(1): 252 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zander, M. P. Sherman, U. Tessmer, K. Bruns, V. Wray, A. T. Prechtel, E. Schubert, P. Henklein, J. Luban, J. Neidleman, et al. Cyclophilin A Interacts with HIV-1 Vpr and Is Required for Its Functional Expression J. Biol. Chem., October 31, 2003; 278(44): 43202 - 43213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Steinschulte, T. Taner, A. W. Thomson, G. Bein, and H. Hackstein Cutting Edge: Sanglifehrin A, a Novel Cyclophilin-Binding Immunosuppressant Blocks Bioactive IL-12 Production by Human Dendritic Cells J. Immunol., July 15, 2003; 171(2): 542 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Clarke, G. P. McStay, and A. P. Halestrap Sanglifehrin A Acts as a Potent Inhibitor of the Mitochondrial Permeability Transition and Reperfusion Injury of the Heart by Binding to Cyclophilin-D at a Different Site from Cyclosporin A J. Biol. Chem., September 13, 2002; 277(38): 34793 - 34799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pahl, M. Zhang, K. Torok, H. Kuss, U. Friedrich, Z. Magyar, J. Szekely, K. Horvath, K. Brune, and I. Szelenyi Anti-Inflammatory Effects of a Cyclosporine Receptor-Binding Compound, D-43787 J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-H. Zhang, H.-D. Youn, and J. O. Liu Inhibition of Cell Cycle Progression by the Novel Cyclophilin Ligand Sanglifehrin A Is Mediated through the NFkappa B-dependent Activation of p53 J. Biol. Chem., November 16, 2001; 276(47): 43534 - 43540. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
